TABLE 1.

Patient characteristics

PatientaGenderbAge (yr)EthnicitycHLA-A2% of blood CD8+ T cells specific for HLA-A*0201-restricted peptidesd in:CD4+ T cellseViral load (Copies/ml)eAntiretroviral therapy
HIV GagHIV PolCMV pp65
PBMCGALTPBMCGALTPBMCGALT
C01M23H+0.000.00NDND0.330.20ND
C02F40C+0.000.000.000.000.020.00ND
G01M54C0.02ND0.02ND0.01ND871<50Yes
G02M33C+0.280.550.02ND1.060.0939472,000No
G03M41C+0.020.020.010.020.680.30136169,000Yes
G04F46C+0.691.200.851.002.020.18170260,000No
G05M35C+0.000.070.00ND3.530.2741713,017No
G10M45C+0.000.000.02ND1.220.072358,000No
G11F44A+0.682.600.02ND0.150.023245,130No
G12M52C+0.170.28NDND0.420.1835012,858No
G13M37A+1.530.570.02ND2.810.41329148,000Yes (6 days)
G22M29C+1.281.220.76ND0.050.03NDNDNo
G25M39A, H+0.180.600.00ND0.130.0467145,378Yes
  • a C01 and C02 are HLA-A*0201-positive, HIV-negative controls. C01 is CMV seropositive, and C02 is CMV seronegative.

  • b M, male; F, female.

  • c C, Caucasian; A, African American; H, Hispanic or Latino.

  • d As determined by tetramer staining. Samples with a distinct tetramer binding population consisting of >0.03% CD8+ T cells were considered positive (see text).

  • e CD4+ T-cell count and viral load were obtained from most recent clinic records.

  • f ND, not determined.